Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 117NIH 12INDUSTRY 10NETWORK 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 5Multiple Myeloma 3Leukemia 3Burkitt Lymphoma 3Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Solid Tumors 1Solid Tumor 1Rhabdomyosarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms by Site 1Nasopharyngeal Carcinoma 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Hodgkin Disease 1Hematopoietic System--Cancer 1Hematologic Neoplasms 1Hematologic Diseases 1Graft vs Host Disease 1Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement 1Disease Progression 1

Interventions

Rituximab 2zanubrutinib 1Prednisone 1Epirubicin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Lymphoma, B-Cell, Marginal Zone × Cyclophosphamide × Clear all
NCT04433156 2026-04-09

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Henan Cancer Hospital

Phase 2 Completed
26 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡